Avoid Savaysa for A Fib if CrCl is OVER 95 mL/min

March 2015

Savaysa (sa-VAYE-sah, edoxaban) will be the fourth new oral anticoagulant (NOAC)...after Pradaxa, Xarelto, and Eliquis.

It's approved for atrial fib and venous thromboembolism (VTE).

But Savaysa has an odd twist when used for A fib. It does NOT work as well as warfarin in patients with NORMAL kidney function.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote